Meiji Holdings Co. Ltd.

03/26/2024 | Press release | Distributed by Public on 03/26/2024 00:07

Meiji Seika Pharma receives Manufacturing and Marketing Approval of REZUROCK® (belumosudil mesilate), a Selective ROCK2 Inhibitor, from MHLW in Japan for the Treatment of cGVHD